Home » Stocks » Royalty Pharma

Royalty Pharma PLC (RPRX)

Stock Price: $40.07 USD -0.16 (-0.40%)
Updated Sep 25, 2020 4:00 PM EDT - Market closed
After-hours: $40.15 +0.08 (0.20%) Sep 25, 7:59 PM

Stock Price Chart

Key Info

Market Cap 24.33B
Revenue (ttm) 1.93B
Net Income (ttm) 2.34B
Shares Out 365.90M
EPS (ttm) n/a
PE Ratio n/a
Forward PE 14.62
Dividend $0.60
Dividend Yield 1.50%

Stock Quote

Trading Day Sep 25, 2020
Last Price $40.07
Previous Close $40.23
Change ($) -0.16
Change (%) -0.40%
Day's Open 39.99
Day's Range 39.90 - 41.20
Day's Volume 882,376
52-Week Range 38.54 - 56.50

More Stats

Market Cap 24.33B
Enterprise Value 26.90B
Earnings Date (est) n/a
Ex-Dividend Date Sep 14, 2020
Shares Outstanding 365.90M
Float 288.67M
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend $0.60
Dividend Yield 1.50%
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 4.59M
Short Ratio 4.63
Short % of Float 1.53%
Beta n/a
PE Ratio n/a
Forward PE 14.62
P/FCF Ratio n/a
PS Ratio 12.58
PB Ratio 5.88
Revenue 1.93B
Operating Income n/a
Net Income 2.34B
Free Cash Flow n/a
Net Cash -2.57B
Net Cash / Share -4.23
Gross Margin 146.55%
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (9)

Buy 3
Overweight 0
Hold 6
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

(29.77% upside)
Current: $40.07
Target: 52.00
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth1.08%12.33%-
Gross Profit1,8141,7951,598
Operating Income2,6231,364940
Net Income2,3491,3781,210
Shares Outstanding595--
Operating Cash Flow1,6671,6181,418
Capital Expenditures-250--
Free Cash Flow1,4171,6181,418
Cash & Equivalents7932,3860.00
Total Debt6,2386,519-
Net Cash / Debt-5,445-4,1330.00
Book Value6,1064,488-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Royalty Pharma PLC
Country United States
CEO Pablo Gerardo Legorreta

Stock Information

Ticker Symbol RPRX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: RPRX
IPO Date June 16, 2020


Royalty Pharma plc operates in the biopharmaceutical industry. The company operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry. It is involved in the identification, evaluation, and acquisition of royalties and royalty-related assets on various biopharmaceutical therapies. The company collaborates with innovators from academic institutions, research hospitals, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio includes royalties on approximately 45 commercial products and three development-stage product candidates. It has royalties on various therapeutic areas and drug classes, including Neulasta, Neupogen, Rituxan, Imbruvica, Trodelvy, Tazverik, and Xtandi in oncology; Lyrica in neuropathic pain; Biktarvy, Genvoya, Prezista, Symtuza, Truvada, and Atripla in HIV; Humira, Remicade, and Cimzia TNF inhibitors; Kalydeco, Orkambi, Symdeko, and Trikafta in cystic fibrosis; Tecfidera and Tysabri in multiple sclerosis; Emgality, Nurtec ODT (rimegepant), and vazegepant in migraine; and others. The company was founded in 1996 and is based in New York, New York.